
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Prepared to a prescriber's order for one patient. Not FDA-approved.
This is a compounded topical gel containing hydroquinone, prepared to a prescriber's order for one patient. Compounded preparations are not FDA-approved.
These listings cover every salt or ester form of each drug in the FDA National Drug Code Directory.
FDA-approved products contain hydroquinone only in combination with other active ingredients, in cream form. No FDA-approved hydroquinone product is listed in gel form; gel products containing it are filed as unapproved drugs.
Gel bases can be aqueous or nonaqueous, and USP <795> classifies the preparation by its water activity. Aqueous preparations carry shorter default beyond-use dates than nonaqueous ones. The date printed on the label is the one to follow.
Hydroquinone is a topical depigmenting agent that compounding pharmacies prepare by prescription in creams, gels and solutions, alone or with tretinoin and a corticosteroid.
Hydroquinone is a skin lightening agent. It inhibits tyrosinase, the enzyme that converts L-DOPA into melanin, so treated skin makes less pigment while the drug is applied; pigment can return after sun exposure or when treatment stops. According to FDA, Tri-Luma (fluocinolone acetonide, hydroquinone and tretinoin cream) is currently the only FDA-approved hydroquinone drug, a prescription product for short-term treatment of moderate to severe melasma of the face, used with sun avoidance. FDA states there are no FDA-approved over-the-counter skin lightening products, that OTC hydroquinone products are unapproved drugs, and that after the CARES Act they are deemed new drugs that cannot be sold without an approved application. A prescriber might order compounded hydroquinone for a single-ingredient preparation, a different strength, a preservative-free vehicle, or a combination with other topical agents. Compounded preparations are not FDA-approved and require a prescription.
Hydroquinone has no boxed warning. Its most serious skin effect is exogenous ochronosis, a gradual blue-black darkening of treated skin that FDA notes may be permanent; risk rises with higher strengths and use beyond about three months, so stop and call your prescriber if any area turns darker instead of lighter. Expect some redness, peeling, burning, dryness or itching; severe irritation, blistering, hives, facial swelling or trouble breathing need medical help right away. FDA has received reports of rashes and facial swelling with OTC lightening products. Tri-Luma contains sodium metabisulfite, and the patient leaflet advises telling your prescriber about any sulfite allergy. Avoid sun and tanning beds, use sunscreen, and use caution with other photosensitizing medicines. Do not apply it to irritated skin. Pregnancy safety has not been established, and the Tri-Luma label notes tretinoin is a teratogen; LactMed found no data on milk transfer, advises keeping the infant's skin away from treated areas, and notes some experts advise against long-term use while nursing. For side effects, talk to your prescriber or pharmacist.
Hydroquinone is a tyrosinase inhibitor that blocks conversion of L-DOPA to melanin, likely through structural similarity to melanin precursors (StatPearls). Percutaneous absorption is meaningful: in vivo human studies show roughly 35% to 45% systemic absorption after topical application of the lower-strength formulations, while the Tri-Luma label reports minimal plasma levels after eight weeks of daily use. Labeled indication: Tri-Luma for short-term treatment of moderate to severe facial melasma with sun avoidance, not for maintenance, not studied in Fitzpatrick types V and VI or in non-melasma hyperpigmentation. FDA's position is that Tri-Luma is the only approved hydroquinone drug and that OTC hydroquinone products are unapproved and not GRASE; prescription single-agent hydroquinone creams described in StatPearls as the standard depigmenting agent for acquired hyperpigmentation therefore sit outside an approved application. Prescribers have ordered compounded hydroquinone, including triple combinations with tretinoin and a corticosteroid, for melasma and postinflammatory hyperpigmentation (StatPearls), off-label. Strength, duration and vehicle are per prescriber. Monitor for hypersensitivity, long-term irritation and early ochronosis, and stop treatment if ochronosis develops; StatPearls also notes falsely elevated glucometer readings and corneal and scleral changes. Hydroquinone is not a controlled substance.
Wash your hands. Apply the amount on your label to clean, dry skin and spread it in a thin layer. For a metered pump, your label states the number of presses. For a dosing syringe, push the plunger to the mark. Let the gel dry before covering with clothing. Wash your hands afterward and keep the site from touching other people until it has dried. Do not apply to broken skin unless told to.
A gel can have a nonaqueous or a water-based base, and USP <795> sets its default beyond-use date by water content, not by the word gel. A nonaqueous gel usually carries a beyond-use date of up to 180 days at room temperature or refrigerated. A water-based gel carries up to 35 days with a preservative, or 14 days refrigerated without one. Your label states which applies. Keep the container closed, away from heat and open flame if it contains alcohol, out of reach of children, and discard after the beyond-use date on your label.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Apply topically to affected area(s)